PK U.S.A., Inc.: PK U.S.A. will be placing Narcan in all three U.S. locations
PK U.S.A. will be placing Narcan in all three U.S. locations
In 2022, over 106,000 United States citizens died from an accidental overdose. In our efforts to ensure the health and safety of our associates, PK U.S.A. will be placing NARCAN at each of our three locations. “If we can help save one life, well, it’s worth every penny,” remarks Bill Kent, Vice President of Corporate Relations.
Naloxone, sold under the brand name Narcan among others, is a medication used to reverse or reduce the effects of opioids. It is used to counter decreased breathing in opioid overdose. Effects begin within two minutes when given intravenously, and within five minutes when injected into a muscle. The medicine can also be administered by spraying it into a person’s nose. Naloxone blocks the effects of opioids for 30 to 90 minutes.
Multiple doses may be required, as the duration of action of some opioids is greater than that of naloxone. Emergency medical services data from the Department of Health and Human Resources found that 93.5% of people given naloxone survived their overdose.
“In a continued effort to ensure the health and safety of everyone at PK U.S.A., we know this is the right choice for all three of our U.S. manufacturing facilities.” Peter Sandström, President.